These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 33568630)

  • 41. Y-box binding protein 1 (YB-1) promotes gefitinib resistance in lung adenocarcinoma cells by activating AKT signaling and epithelial-mesenchymal transition through targeting major vault protein (MVP).
    Lou L; Wang J; Lv F; Wang G; Li Y; Xing L; Shen H; Zhang X
    Cell Oncol (Dordr); 2021 Feb; 44(1):109-133. PubMed ID: 32894437
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance.
    Kim S; Im JH; Kim WK; Choi YJ; Lee JY; Kim SK; Kim SJ; Kwon SW; Kang KW
    Oxid Med Cell Longev; 2021; 2021():5428364. PubMed ID: 34367462
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer.
    Fu S; Liu C; Huang Q; Fan S; Tang H; Fu X; Ai B; Liao Y; Chu Q
    Oncol Rep; 2018 Mar; 39(3):1313-1321. PubMed ID: 29328407
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fucoxanthin extracted from Laminaria Japonica inhibits metastasis and enhances the sensitivity of lung cancer to Gefitinib.
    Ming JX; Wang ZC; Huang Y; Ohishi H; Wu RJ; Shao Y; Wang H; Qin MY; Wu ZL; Li YY; Chang Zhou S; Chen H; Liu H; Xu R
    J Ethnopharmacol; 2021 Jan; 265():113302. PubMed ID: 32860893
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Paeoniae radix overcomes resistance to EGFR-TKIs via aurora B pathway suppression in lung adenocarcinoma.
    Yeo H; Lee H; Park SM; Kang HN
    Life Sci; 2024 Nov; 357():123097. PubMed ID: 39362582
    [TBL] [Abstract][Full Text] [Related]  

  • 46. DUS4L suppresses invasion and metastasis in LUAD via modulation of PI3K/AKT and ERK/MAPK signaling through GRB2.
    Li Z; Zhao PL; Gao X; Li X; Meng YQ; Li ZQ; Zhai KR; Wei SL; Feng HM; Huang HR; Li B
    Int Immunopharmacol; 2024 Dec; 142(Pt A):113043. PubMed ID: 39216120
    [TBL] [Abstract][Full Text] [Related]  

  • 47. L-Methionine accentuates anti-tumor action of Gefitinib in Gefitinib-resistant lung adenocarcinoma: Role of EGFR/ERK/AKT signaling and histone H3K36me2 alteration.
    Pal S; Kabeer SW; Tikoo K
    Toxicol Appl Pharmacol; 2024 Apr; 485():116907. PubMed ID: 38521369
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Knockdown of HE4 suppresses tumor growth and invasiveness in lung adenocarcinoma through regulation of EGFR signaling.
    Zhang Y; Yang W; Han X; Qiao Y; Wang H; Chen T; Li T; Ou WB
    Oncol Res; 2024; 32(6):1119-1128. PubMed ID: 38827327
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
    Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
    Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
    [TBL] [Abstract][Full Text] [Related]  

  • 50. KIAA1429 promotes tumorigenesis and gefitinib resistance in lung adenocarcinoma by activating the JNK/ MAPK pathway in an m
    Lin X; Ye R; Li Z; Zhang B; Huang Y; Du J; Wang B; Meng H; Xian H; Yang X; Zhang X; Zhong Y; Huang Z
    Drug Resist Updat; 2023 Jan; 66():100908. PubMed ID: 36493511
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor.
    Rong X; Liang Y; Han Q; Zhao Y; Jiang G; Zhang X; Lin X; Liu Y; Zhang Y; Han X; Zhang M; Luo Y; Li P; Wei L; Yan T; Wang E
    J Thorac Oncol; 2019 Oct; 14(10):1766-1783. PubMed ID: 31228625
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FTO/m6A mediates miR-138-5p maturation and regulates gefitinib resistance of lung adenocarcinoma cells by miR-138-5p/LCN2 axis.
    Ding D; Shang W; Shi K; Ying J; Wang L; Chen Z; Zhang C
    BMC Cancer; 2024 Oct; 24(1):1270. PubMed ID: 39394098
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Exosomes transmit T790M mutation-induced resistance in EGFR-mutant NSCLC by activating PI3K/AKT signalling pathway.
    Liu X; Jiang T; Li X; Zhao C; Li J; Zhou F; Zhang L; Zhao S; Jia Y; Shi J; Gao G; Li W; Zhao J; Chen X; Su C; Ren S; Zhou C
    J Cell Mol Med; 2020 Jan; 24(2):1529-1540. PubMed ID: 31894895
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SLC39A5 promotes lung adenocarcinoma cell proliferation by activating PI3K/AKT signaling.
    Liu Z; Hu Z; Cai X; Liu S
    Pathol Res Pract; 2021 Aug; 224():153541. PubMed ID: 34252710
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Depleting hsa_circ_0000567 suppresses acquired gefitinib resistance and proliferation of lung adenocarcinoma cells through regulating the miR-377-3p / ZFX axis: an in vitro and in vivo study.
    Wang L; Li M; Lian R
    Histol Histopathol; 2022 Jul; 37(7):637-654. PubMed ID: 35133000
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer.
    Hidayat M; Mitsuishi Y; Takahashi F; Tajima K; Yae T; Miyahara K; Hayakawa D; Winardi W; Ihara H; Koinuma Y; Wirawan A; Nurwidya F; Kato M; Kobayashi I; Sasaki S; Takamochi K; Hayashi T; Suehara Y; Moriyama M; Moriyama H; Habu S; Takahashi K
    Bosn J Basic Med Sci; 2019 Nov; 19(4):355-367. PubMed ID: 31202256
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
    Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
    Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Axl is a novel target of celastrol that inhibits cell proliferation and migration, and increases the cytotoxicity of gefitinib in EGFR mutant non‑small cell lung cancer cells.
    Lee YJ; Kim SY; Lee C
    Mol Med Rep; 2019 Apr; 19(4):3230-3236. PubMed ID: 30816529
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HCP5 is a SMAD3-responsive long non-coding RNA that promotes lung adenocarcinoma metastasis via miR-203/SNAI axis.
    Jiang L; Wang R; Fang L; Ge X; Chen L; Zhou M; Zhou Y; Xiong W; Hu Y; Tang X; Li G; Li Z
    Theranostics; 2019; 9(9):2460-2474. PubMed ID: 31131047
    [No Abstract]   [Full Text] [Related]  

  • 60. CD73 (NT5E) Promotes the Proliferation and Metastasis of Lung Adenocarcinoma through the EGFR/AKT/mTOR Pathway.
    Zhang H; Cao Y; Tang J; Wang R
    Biomed Res Int; 2022; 2022():9944847. PubMed ID: 35813221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.